CSF and clinical hallmarks of subcortical dementias

Focus on DLB and PDD

Alessandro Stefani, Livia Brusa, Enrica Olivola, Mariangela Pierantozzi, Alessandro Martorana

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Dementia has become a relevant problem associated with the elderly in our countries. Increased interest in the field has yielded a copious literature, so far mostly centered on Alzheimer's dementia. Cerebrospinal fluid (CSF) analysis combined with neuropsychology, even in absence of neuroimaging, represents the gold standard to reach a diagnosis when cortical cognitive impairment prevails. In view of this, low levels of CSF amyloid peptides β (Aβ) and high tau/Aβ protein ratio, despite prominent impairment of executive functions or concomitant vascular burden, facilitate the diagnosis of Alzheimer's disease. Conversely, an early cognitive impairment occurring in patients suffering from Parkinson's disease (PD) or Lewy body disorders (LBDs), both diagnoses posed on pure clinical grounds, remains quite elusive in term of biomarkers or neuropsychological assessment. Whether PD with dementia (PDD) and dementia with Lewy bodies (DLB) represent further steps along with a continuum of the same progressive degeneration due to Lewy bodies deposition, rather then the association of Lewy bodies and Aβ pathology, remains a challenging issue. Aim of this work is to set a state-of-the-art on the neuropsychological profiles of both or DLB. Then, we will focus on the ongoing controversies about the specificity of the standard CSF biomarkers if applied to extrapyramidal disorders. Our conclusions are that the CSF pattern, in PDD and DLB, can certainly be distinct from that in AD, though mechanisms leading to dementia could be shared among them. It is possible that, by combining imaging tracers, neuropsychologically careful assessment and renewed CSF biomarkers, DLB can be better distinguished in subgroups, depending on the presence or absence of a relevant amyloid burden. However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities.

Original languageEnglish
Pages (from-to)861-875
Number of pages15
JournalJournal of Neural Transmission
Volume119
Issue number7
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Lewy Body Disease
Cerebrospinal Fluid
Dementia
Lewy Bodies
Aptitude
Biomarkers
Amyloid
Parkinson Disease
Alzheimer Disease
Basal Ganglia Diseases
Neuropsychology
tau Proteins
Executive Function
Neuroimaging
Blood Vessels
Pathology

Keywords

  • CSF biomarkers
  • Dementia
  • Lewi body disorders
  • Parkinson's disease

ASJC Scopus subject areas

  • Biological Psychiatry
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Stefani, A., Brusa, L., Olivola, E., Pierantozzi, M., & Martorana, A. (2012). CSF and clinical hallmarks of subcortical dementias: Focus on DLB and PDD. Journal of Neural Transmission, 119(7), 861-875. https://doi.org/10.1007/s00702-012-0820-0

CSF and clinical hallmarks of subcortical dementias : Focus on DLB and PDD. / Stefani, Alessandro; Brusa, Livia; Olivola, Enrica; Pierantozzi, Mariangela; Martorana, Alessandro.

In: Journal of Neural Transmission, Vol. 119, No. 7, 07.2012, p. 861-875.

Research output: Contribution to journalArticle

Stefani, A, Brusa, L, Olivola, E, Pierantozzi, M & Martorana, A 2012, 'CSF and clinical hallmarks of subcortical dementias: Focus on DLB and PDD', Journal of Neural Transmission, vol. 119, no. 7, pp. 861-875. https://doi.org/10.1007/s00702-012-0820-0
Stefani, Alessandro ; Brusa, Livia ; Olivola, Enrica ; Pierantozzi, Mariangela ; Martorana, Alessandro. / CSF and clinical hallmarks of subcortical dementias : Focus on DLB and PDD. In: Journal of Neural Transmission. 2012 ; Vol. 119, No. 7. pp. 861-875.
@article{14515cdfd66647a6af64b4f1399eca88,
title = "CSF and clinical hallmarks of subcortical dementias: Focus on DLB and PDD",
abstract = "Dementia has become a relevant problem associated with the elderly in our countries. Increased interest in the field has yielded a copious literature, so far mostly centered on Alzheimer's dementia. Cerebrospinal fluid (CSF) analysis combined with neuropsychology, even in absence of neuroimaging, represents the gold standard to reach a diagnosis when cortical cognitive impairment prevails. In view of this, low levels of CSF amyloid peptides β (Aβ) and high tau/Aβ protein ratio, despite prominent impairment of executive functions or concomitant vascular burden, facilitate the diagnosis of Alzheimer's disease. Conversely, an early cognitive impairment occurring in patients suffering from Parkinson's disease (PD) or Lewy body disorders (LBDs), both diagnoses posed on pure clinical grounds, remains quite elusive in term of biomarkers or neuropsychological assessment. Whether PD with dementia (PDD) and dementia with Lewy bodies (DLB) represent further steps along with a continuum of the same progressive degeneration due to Lewy bodies deposition, rather then the association of Lewy bodies and Aβ pathology, remains a challenging issue. Aim of this work is to set a state-of-the-art on the neuropsychological profiles of both or DLB. Then, we will focus on the ongoing controversies about the specificity of the standard CSF biomarkers if applied to extrapyramidal disorders. Our conclusions are that the CSF pattern, in PDD and DLB, can certainly be distinct from that in AD, though mechanisms leading to dementia could be shared among them. It is possible that, by combining imaging tracers, neuropsychologically careful assessment and renewed CSF biomarkers, DLB can be better distinguished in subgroups, depending on the presence or absence of a relevant amyloid burden. However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities.",
keywords = "CSF biomarkers, Dementia, Lewi body disorders, Parkinson's disease",
author = "Alessandro Stefani and Livia Brusa and Enrica Olivola and Mariangela Pierantozzi and Alessandro Martorana",
year = "2012",
month = "7",
doi = "10.1007/s00702-012-0820-0",
language = "English",
volume = "119",
pages = "861--875",
journal = "Journal of Neural Transmission",
issn = "0300-9564",
publisher = "Springer-Verlag Wien",
number = "7",

}

TY - JOUR

T1 - CSF and clinical hallmarks of subcortical dementias

T2 - Focus on DLB and PDD

AU - Stefani, Alessandro

AU - Brusa, Livia

AU - Olivola, Enrica

AU - Pierantozzi, Mariangela

AU - Martorana, Alessandro

PY - 2012/7

Y1 - 2012/7

N2 - Dementia has become a relevant problem associated with the elderly in our countries. Increased interest in the field has yielded a copious literature, so far mostly centered on Alzheimer's dementia. Cerebrospinal fluid (CSF) analysis combined with neuropsychology, even in absence of neuroimaging, represents the gold standard to reach a diagnosis when cortical cognitive impairment prevails. In view of this, low levels of CSF amyloid peptides β (Aβ) and high tau/Aβ protein ratio, despite prominent impairment of executive functions or concomitant vascular burden, facilitate the diagnosis of Alzheimer's disease. Conversely, an early cognitive impairment occurring in patients suffering from Parkinson's disease (PD) or Lewy body disorders (LBDs), both diagnoses posed on pure clinical grounds, remains quite elusive in term of biomarkers or neuropsychological assessment. Whether PD with dementia (PDD) and dementia with Lewy bodies (DLB) represent further steps along with a continuum of the same progressive degeneration due to Lewy bodies deposition, rather then the association of Lewy bodies and Aβ pathology, remains a challenging issue. Aim of this work is to set a state-of-the-art on the neuropsychological profiles of both or DLB. Then, we will focus on the ongoing controversies about the specificity of the standard CSF biomarkers if applied to extrapyramidal disorders. Our conclusions are that the CSF pattern, in PDD and DLB, can certainly be distinct from that in AD, though mechanisms leading to dementia could be shared among them. It is possible that, by combining imaging tracers, neuropsychologically careful assessment and renewed CSF biomarkers, DLB can be better distinguished in subgroups, depending on the presence or absence of a relevant amyloid burden. However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities.

AB - Dementia has become a relevant problem associated with the elderly in our countries. Increased interest in the field has yielded a copious literature, so far mostly centered on Alzheimer's dementia. Cerebrospinal fluid (CSF) analysis combined with neuropsychology, even in absence of neuroimaging, represents the gold standard to reach a diagnosis when cortical cognitive impairment prevails. In view of this, low levels of CSF amyloid peptides β (Aβ) and high tau/Aβ protein ratio, despite prominent impairment of executive functions or concomitant vascular burden, facilitate the diagnosis of Alzheimer's disease. Conversely, an early cognitive impairment occurring in patients suffering from Parkinson's disease (PD) or Lewy body disorders (LBDs), both diagnoses posed on pure clinical grounds, remains quite elusive in term of biomarkers or neuropsychological assessment. Whether PD with dementia (PDD) and dementia with Lewy bodies (DLB) represent further steps along with a continuum of the same progressive degeneration due to Lewy bodies deposition, rather then the association of Lewy bodies and Aβ pathology, remains a challenging issue. Aim of this work is to set a state-of-the-art on the neuropsychological profiles of both or DLB. Then, we will focus on the ongoing controversies about the specificity of the standard CSF biomarkers if applied to extrapyramidal disorders. Our conclusions are that the CSF pattern, in PDD and DLB, can certainly be distinct from that in AD, though mechanisms leading to dementia could be shared among them. It is possible that, by combining imaging tracers, neuropsychologically careful assessment and renewed CSF biomarkers, DLB can be better distinguished in subgroups, depending on the presence or absence of a relevant amyloid burden. However, more complete data, possibly collected in fieri during the progressive derangement of cognitive abilities, are needed to improve our ability to decipher and treat these entities.

KW - CSF biomarkers

KW - Dementia

KW - Lewi body disorders

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=84863499312&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863499312&partnerID=8YFLogxK

U2 - 10.1007/s00702-012-0820-0

DO - 10.1007/s00702-012-0820-0

M3 - Article

VL - 119

SP - 861

EP - 875

JO - Journal of Neural Transmission

JF - Journal of Neural Transmission

SN - 0300-9564

IS - 7

ER -